Celularity Settles Default Claims with Helena for $1M Cash and $2.5M Note Assignment
CELU sits 40% above its 52-week low of $0.71.
Summary
Celularity Inc. has entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd. to resolve existing claims and a prior event of default, involving $1 million in cash payments and the assignment of a $2.5 million promissory note.
Key Events · Legal and Risk Events · CELU
-
Settlement of Default
Celularity resolved existing claims and a prior event of default with Helena Global Investment Opportunities 1 Ltd., which had previously exchanged preferred stock for a convertible note and issued a default notice (as disclosed in an 8-K on April 21, 2026).
-
Financial Terms
The settlement includes an immediate $500,000 cash payment, five subsequent monthly payments of $100,000 each (totaling $1 million), and the assignment of a $2.5 million promissory note from NEXGEL, Inc. to Helena.
-
Restructured Obligations
Helena surrendered its Series A Convertible Preferred Stock, and the company's new payment obligations are secured by an amended security agreement, replacing the prior defaulted note.
Analysis · CELU · Life Sciences
This settlement is a critical step for Celularity, which recently disclosed "going concern" issues and faced a default notice from Helena Global Investment Opportunities 1 Ltd. While the company is committing $1 million in cash and assigning a $2.5 million promissory note, the resolution of this significant financial dispute removes a major overhang and potential legal action, providing much-needed stability. The assignment of the NEXGEL note means Celularity will not receive those future payments directly, but it eliminates a problematic preferred stock and note obligation. This action follows the company's recent 10-K filing to regain Nasdaq compliance, suggesting a concerted effort to address financial challenges.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.7M. The 52-week trading range was $0.71 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.